DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

IBEX Technologies Inc.

TSXV:IBT Stock Report

Market Cap: CA$35.3m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IBEX Technologies Past Earnings Performance

Past criteria checks 5/6

IBEX Technologies has been growing earnings at an average annual rate of 58%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 14.1% per year. IBEX Technologies's return on equity is 27.9%, and it has net margins of 49.7%.

Key information

58.00%

Earnings growth rate

57.08%

EPS growth rate

Biotechs Industry Growth51.09%
Revenue growth rate14.08%
Return on equity27.93%
Net Margin49.70%
Last Earnings Update31 Jan 2024

Recent past performance updates

Analysis Article • Dec 22

IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They Seem

Following the release of a positive earnings report recently, IBEX Technologies Inc.'s ( CVE:IBT ) stock performed...

Recent updates

Analysis Article • Feb 13

The Market Lifts IBEX Technologies Inc. (CVE:IBT) Shares 27% But It Can Do More

Despite an already strong run, IBEX Technologies Inc. ( CVE:IBT ) shares have been powering on, with a gain of 27% in...
Analysis Article • Dec 22

IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They Seem

Following the release of a positive earnings report recently, IBEX Technologies Inc.'s ( CVE:IBT ) stock performed...
Analysis Article • Dec 19

Market Might Still Lack Some Conviction On IBEX Technologies Inc. (CVE:IBT) Even After 28% Share Price Boost

Those holding IBEX Technologies Inc. ( CVE:IBT ) shares would be relieved that the share price has rebounded 28% in the...
Analysis Article • Oct 05

Calculating The Fair Value Of IBEX Technologies Inc. (CVE:IBT)

Key Insights Using the 2 Stage Free Cash Flow to Equity, IBEX Technologies fair value estimate is CA$0.99 With CA$0.99...
Analysis Article • May 22

A Look At The Fair Value Of IBEX Technologies Inc. (CVE:IBT)

Key Insights IBEX Technologies' estimated fair value is CA$0.74 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article • Jan 19

Shareholders May Be More Conservative With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation For Now

Key Insights IBEX Technologies to hold its Annual General Meeting on 25 January 2023 CEO Paul Baehr's total...
Analysis Article • Feb 10

We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation

We have been pretty impressed with the performance at IBEX Technologies Inc. ( CVE:IBT ) recently and CEO Paul Baehr...
Analysis Article • Mar 25

Investors Shouldn't Be Too Comfortable With IBEX Technologies' (CVE:IBT) Robust Earnings

IBEX Technologies Inc.'s ( CVE:IBT ) robust earnings report didn't manage to move the market for its stock. Our...
Analysis Article • Feb 22

IBEX Technologies Inc.'s (CVE:IBT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

IBEX Technologies' (CVE:IBT) stock is up by a considerable 11% over the past month. Given that stock prices are usually...
Analysis Article • Dec 29

How Should Investors React To IBEX Technologies' (CVE:IBT) CEO Pay?

Paul Baehr is the CEO of IBEX Technologies Inc. ( CVE:IBT ), and in this article, we analyze the executive's...

Revenue & Expenses Breakdown

How IBEX Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:IBT Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jan 248441
31 Oct 238431
31 Jul 237431
30 Apr 238231
31 Jan 238131
31 Oct 228230
31 Jul 228230
30 Apr 227230
31 Jan 226120
31 Oct 216120
31 Jul 215120
30 Apr 215120
31 Jan 216120
31 Oct 205120
31 Jul 205120
30 Apr 205020
31 Jan 204-120
31 Oct 194-120
31 Jul 194-120
30 Apr 194-120
31 Jan 195020
31 Oct 185020
31 Jul 185020
30 Apr 185220
31 Jan 185220
31 Oct 175320
31 Jul 175320
30 Apr 175120
31 Jan 174020
31 Oct 164020
31 Jul 164020
30 Apr 165120
31 Jan 165120
31 Oct 154120
31 Jul 153020
30 Apr 153-120
31 Jan 153-120
31 Oct 144020
31 Jul 144020
30 Apr 144020
31 Jan 144020
31 Oct 134020
31 Jul 134020
30 Apr 134-120

Quality Earnings: IBT has a high level of non-cash earnings.

Growing Profit Margin: IBT's current net profit margins (49.7%) are higher than last year (17.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IBT's earnings have grown significantly by 58% per year over the past 5 years.

Accelerating Growth: IBT's earnings growth over the past year (187.4%) exceeds its 5-year average (58% per year).

Earnings vs Industry: IBT earnings growth over the past year (187.4%) exceeded the Biotechs industry -8.9%.


Return on Equity

High ROE: IBT's Return on Equity (27.9%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/08 17:03
End of Day Share Price 2024/04/08 00:00
Earnings2024/01/31
Annual Earnings2023/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IBEX Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide